Therapeutic Advances in Drug Safety

Therapeutic Advances in Drug Safety is a peer-reviewed journal from SAGE Publications in London, founded in October 2010 for work on the safe use of medicines in patients.《药物治疗进展（药物安全）》由伦敦的 SAGE 出版，2010 年 10 月创刊，是一本关注患者安全用药的同行评议期刊。

A strong clinical and pharmacological focus shapes the title, which addresses clinicians, pharmacists and drug safety researchers and appears in print as well as online.期刊以临床与药理为重心，面向临床医师、药师与药物安全研究者，同时发行印刷版与网络版。

Research articles, reviews and scholarly comment on pioneering efforts and innovative studies anchor each volume, with room for contested questions about how medicines are watched after approval.每卷以研究论文与综述为主体，并刊登针对开创性工作的学术评论，也接纳关于上市后药品监管的争议性议题。

Its 2025 Journal Impact Factor is 3.3, the five-year value is 4.2, and the Journal Citation Reports place it in the second quartile of Pharmacology and Pharmacy.2025 年的影响因子为 3.3，五年影响因子为 4.2，在《期刊引证报告》的药理学与药学类中处于第二四分位。

Scope

• The stated aim is to publish the highest quality peer-reviewed articles, reviews and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs.期刊公布的宗旨是发表与安全用药相关的优质同行评议论文与综述，并刊载评述开创性工作与创新研究的学术评论。
• Therapeutic drug monitoring receives sustained attention, from assay performance and sampling schedules to the interpretation of concentrations in individual patients and special populations.治疗药物监测受到持续关注，涵盖检测方法性能与采样安排，也涉及个体患者与特殊人群的血药浓度解读。
• Pharmacoepidemiology and real-world evidence supply much of the empirical base, including database studies of prescribing patterns and outcomes across national health systems.药物流行病学与真实世界证据构成主要的实证来源，其中包括基于数据库的处方模式与结局研究。
• Adverse drug reactions are studied from detection and phenotyping through to causality assessment, with spontaneous reports and registry data analysed side by side.药物不良反应的研究从识别与表型划分延伸到因果判定，自发报告与登记数据常被并列分析。
• Drug interactions form a recurring theme, covering metabolic and transporter mechanisms as well as interactions with alcohol, food and co-prescribed medicines.药物相互作用是反复出现的主题，既讨论代谢与转运体机制，也讨论与酒精、食物以及其他合并用药之间的相互影响。
• Pharmacokinetic and pharmacogenetic variation appears in work on dose individualisation, where genotype and organ function reshape exposure and the risk of toxicity.药代动力学与药物遗传学差异体现在剂量个体化的研究中，基因型与器官功能会改变药物暴露和毒性风险。
• Pharmacovigilance practice is treated as a subject in its own right, spanning signal detection, benefit-risk assessment, regulatory communication and the evaluation of safety alerts.药物警戒实践被视为独立议题，涉及信号检测、获益风险评估、监管沟通与安全警示的效果评价。
• Medication and prescribing errors, including look-alike names and dosing slips, are examined together with the interventions meant to stop them recurring.用药与处方差错受到关注，包括形似药名与剂量失误，也考察用于防止其重复发生的干预措施。
• Risk management is covered closely, from risk minimisation measures and pregnancy prevention programmes to the measurement of their effect in routine care.风险管理得到细致讨论，从风险最小化措施与妊娠预防计划，到这些措施在常规诊疗中的效果测量。
• Ethics and regulation of drug safety are handled as policy questions, including transparency of trial data, labelling decisions and governance of post-marketing studies.药物安全的伦理与监管被当作政策问题处理，涵盖试验数据透明度、说明书决策与上市后研究的治理。
• Older adults and other vulnerable groups feature in studies of polypharmacy, deprescribing and potentially inappropriate prescribing in primary and secondary care.老年人及其他脆弱人群常出现在多重用药、减停药物与潜在不适当处方的研究中，场景覆盖基层与专科诊疗。
• Vaccine and biologic safety has become a visible strand, with analyses of reported events and of the trade-off between protection and rare harms.疫苗与生物制品安全性已成为显眼的板块，研究涉及报告事件的分析，以及保护作用与罕见损害之间的权衡。
• Artificial intelligence and machine learning now appear in work on case processing, disproportionality analysis and the use of large language models to flag drug interactions.人工智能与机器学习进入个案处理、不相称性分析等工作，也用于以大型语言模型识别药物相互作用。
• Submissions may arrive as original research, systematic and narrative reviews, case reports or commentary, and themed Special Collections gather papers around a single safety problem.稿件形式包括原创研究、系统综述与叙述性综述、病例报告及评论，主题专集则围绕单一安全问题汇集论文。

History

• Volume 1, number 1 appeared in October 2010, when SAGE set up the title in London during a wider expansion of its clinical and open access list.第 1 卷第 1 期于 2010 年 10 月面世，当时 SAGE 正在伦敦扩充其临床与开放获取期刊阵容。
• The opening issues carried an editorial signed by Arduino A. Mangoni, alongside reviews on anticoagulants in older people, drug-induced liver injury and medication error taxonomies.创刊初期刊登了 Arduino A. Mangoni 执笔的社论，并配以老年抗凝药安全、药物性肝损伤与用药差错分类学的综述。
• The journal belongs to the Therapeutic Advances series, now 20 titles, which SAGE presents as an established high-quality gold open access family of journals.期刊隶属于 Therapeutic Advances 系列，该系列现有 20 种刊物，SAGE 将其定位为成熟的优质金色开放获取刊群。
• Early volumes were bimonthly, six issues a year, and the National Library of Medicine still records that schedule although it has long been superseded.早期各卷为双月刊，每年 6 期，美国国家医学图书馆至今仍沿用这一著录，尽管它早已不再准确。
• By 2016 the title had moved to monthly publication, twelve issues a year, with volume 8 running from issue 1 to issue 12 across 2016 and 2017.到 2016 年已改为月刊，每年 12 期，第 8 卷在 2016 至 2017 年间从第 1 期连续出到第 12 期。
• Issue numbers were then dropped. Crossref treats volume 10 onward as article-level publication, and volumes 14 to 17 carry no issue field at all.此后期号被取消，Crossref 将第 10 卷起的记录按单篇著录，第 14 至 17 卷已完全没有期号字段。
• One volume now corresponds to one calendar year, so volume 1 is 2010, volume 16 is 2025 and volume 17 is the current 2026 run.现在每卷对应一个自然年，第 1 卷为 2010 年，第 16 卷为 2025 年，第 17 卷是进行中的 2026 年。
• All content is free to read. The Journal Citation Reports count 100 per cent of output as gold open access, and the Directory of Open Access Journals lists the title.全部内容可免费阅读，据《期刊引证报告》统计金色开放获取论文占比为 100%，该刊也收录于开放获取期刊目录。
• PubMed has indexed the journal from volume 1 in 2010 and articles are deposited in PubMed Central, while Clarivate includes it in Science Citation Index Expanded.PubMed 自 2010 年第 1 卷起收录该刊，论文同时存入 PubMed Central，科睿唯安将其纳入 SCIE。
• JCR 2025 puts the journal at rank 149 of 356 in Pharmacology and Pharmacy, with a Journal Citation Indicator of 0.75 and a cited half-life of 7.2 years.《期刊引证报告》2025 年在药理学与药学类 356 种期刊中将其排在第 149 位，期刊引证指标为 0.75，被引半衰期为 7.2 年。
• Output has grown in the continuous era. Crossref counts 28 records for 2023, 51 for 2024 and 68 for 2025, against 53 citable items in the JCR window.连续出版阶段的发文量上升，Crossref 记录 2023 年 28 篇、2024 年 51 篇、2025 年 68 篇，而《期刊引证报告》统计的可引用论文为 53 篇。
• The title has never been renamed, and ISSN 2042-0986 has followed it through every change of frequency, format and business model since 2010.刊名从未更改，ISSN 2042-0986 伴随该刊经历了 2010 年以来的刊期、版式与经营模式变化。

Editors

• SAGE describes the journal as edited by a diverse and experienced editorial team and directs readers to a separate board page for the full roster.SAGE 称该刊由一个多元且经验丰富的编辑团队主持，并引导读者前往独立的编委页面查看完整名单。
• That board sits behind an entry of its own in the journal menu, next to the journal overview, submission guidelines and reprints pages.编委会在期刊菜单中单独成项，与期刊概览、投稿指南及转载授权并列。
• Editorial work is shared across the Therapeutic Advances series, whose 20 gold open access titles draw on common production and peer review arrangements.编辑工作与 Therapeutic Advances 系列共享，该系列 20 种金色开放获取刊物沿用共通的生产与评议安排。
• Every research paper and review passes external peer review before acceptance, and the journal declares its membership of the Committee on Publication Ethics on its home page.所有研究论文与综述在录用前均经过外部同行评议，期刊首页也声明其为出版伦理委员会成员。
• The editors say they welcome articles of current interest across every area of drug safety, which leaves room for agenda-setting reviews as well as unsolicited research.编辑部表示欢迎覆盖药物安全各个领域的时新稿件，这既能容纳设定议题的综述，也容纳非约稿的研究。
• A highlighted section on the home page collects articles hand-picked by the editors, an editorial filter that sits alongside ordinary acceptance decisions.首页的精选栏目汇集由编辑亲自挑选的论文，这一编辑层面的筛选与常规录用决定并行。
• Special Collections are curated by guest editors, who apply through a proposal form and follow published guidance before taking charge of a themed set.主题专集由客座编辑主持，需先通过提案表申请，并遵循已公布的指南，方可负责一组主题论文。
• Case reports reach the board alongside research and reviews, so editors weight single-patient evidence against the journal's preference for population-level safety data.病例报告与研究论文、综述一同进入编辑视野，编辑需要在单例证据与期刊偏好的群体层面安全数据之间权衡。
• Accepted papers appear online with a first publication date before they are assigned to a volume, a sequence the editorial office manages article by article.录用论文先以首次上线日期发布，随后才归入某一卷，这一顺序由编辑部逐篇安排。
• Corrections and retractions follow the publisher's ethics guidance, and the board's handling of such notices is recorded on the published record.更正与撤稿遵循出版方的伦理指引，编委会对此类声明的处理会记录在已发表记录之上。